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Osteonecrosis of the jaw (ONJ) is one of the most relevant and speciﬁc complication of biphosphonates.
ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly
regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reported. A literature
review, focusing on the important trials using zoledronic acid to reduce AIBL, found that the mean risk of
developing ONJ when zoledronic acid is used biyearly varies between 0.12% and 0.7%.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteonecrosis of the jaw (ONJ) emerged as a well-known de-
vastating side effect of parenteral bisphosphonate therapy since
the widespread use of biphosphonates to reduce skeletal related
events (SRE) [1]. Biphosphonates are commonly used every three
to four weeks with around 14–48% reduction of SRE occurrence
and ONJ occurrence in 1.2–3.8% despite preventive measures [2–
5].
Although the positive results of 4 different trials, the use of
biyearly biphosphonates regimens to reduce AIBL is NOT approved
[6–9]. This spaced interval of six months achieved an increase in
median bone mineral density of 2.7–4.3% in the lumbar spine and
1.6–1.7% in the hip when used in post-menopausal women re-
ceiving adjuvant hormonal aromatase inhibitor [7,8]. However, the
risk of developing ONJ with the bi-annually regimen of zoledronic
acid is not well recognized.
A review of literature in women having breast cancer receiving
zoledronate biannually to prevent AIBL was conducted. Reported
cases of ONJ are collected from the selected studies and an esti-
mation of the ONJ risk in this category of patients is reported.GmbH. This is an open access art
. Kourie).2. Material and methods
2.1. Search strategy for the identiﬁcation of studies
Electronic searches of the literature published until September
2014 were conducted using PubMed and the Cochrane Colla-
boration Database to identify articles evaluating the ONJ as a side
effect in women receiving zoledronic acid every six months for the
prevention of aromatase inhibitor associated bone loss (AIBL) in
patients with early stage breast cancer.
Only randomized and non-randomized controlled clinical trials
were included. We excluded studies enrolling less than 500 pa-
tients. The duration of follow-up was not among the exclusion
criteria. Search strategies employed included key words and
Boolean operators described as follows: ‘zoledronic acid’, ‘early
breast cancer’ and ‘aromatase inhibitors’. This search was aug-
mented by a hand search of the reference lists of relevant articles
included in the literature review. Two different investigators per-
formed the search and the abstracts were independently reviewed
for possible inclusion.
2.2. Selection criteria
Types of studies: Randomized controlled trials were included. The
language of publication of eligible studies was restricted to English.icle under the CC BY-NC-ND license
H.R. Kourie et al. / Journal of Bone Oncology 4 (2015) 77–7978Types of Participants: Included studies were limited to post-
menopausal women receiving zoledronic acid every six months
with aromatase inhibitors to prevent AIBL. Studies presenting data
on premenopausal patients or receiving tamoxifen were excluded.
Selection of Studies: The articles were ﬁrst selected individually
on the basis of their titles by two of the authors. Then, the ab-
stracts of the available articles were examined. Our searches
yielded 81 study reports from the PubMed database. All the review
articles and case reports were excluded. Finally, four reports were
considered illegible for our analysis [6–9]. Some of the other stu-
dies were included in the literature review.3. Results
The upfront biyearly regimen of zoledronic acid signiﬁcantly
increased bone mineral density (BMD) in postmenopausal women
receiving aromatase inhibitors for early breast cancer [6–9].
The Z-FAST trial enrolled 602 postmenopausal women with
early hormone receptor-positive breast cancer receiving adjuvant
letrozole [6]. Patients were randomized equally to receive upfront
or delayed zoledronic acid with a 4 mg intravenous regimen every
6 months for 5 years. The investigators reported two cases of ONJ
in the upfront group during the 60 months follow-up. However, an
ONJ adjudication committee deemed one of the cases inconsistent
with ONJ and the other one indeterminate because of insufﬁcient
information [6].
The ZO-FAST trial recruited 1065 postmenopausal women re-
ceiving adjuvant letrozole that were randomly assigned to im-
mediate zoledronic acid with a regimen of 4 mg every 6 months
for 5 years, or delayed administration initiated at fracture occur-
rence or on-study BMD decrease. A total of nine potential ONJ
events from seven patients were reported in this study after 60
months follow up. Each event was independently adjudicated by
an external panel that conﬁrmed ONJ occurrence in three cases,
deemed possible for insufﬁcient data in two cases, and excluded
the remaining cases [7]. Therefore, in the ZO-FAST trial, ONJ oc-
curred in 0.28–0.47%.
In the E-ZO-FAST trial, 527 postmenopausal women receiving
aromatase inhibitors were randomized to either immediate or
delayed zoledronic acid treatment, at 4 mg every 6 months. Two
reported cases of ONJ of the immediate zoledronic acid group were
conﬁrmed by the adjudication committee. At diagnosis, patients
had received 3 and 6 doses of zoledronic acid. Treatment was
discontinued in both patients but ONJ only resolved in one patient
[8]. Accordingly, the E-ZO-FAST trial report ONJ in 0.38%.
Finally, the ABCSG-12 trial is the largest study recruiting 1803
patients with early breast cancer receiving zoledronic acid 4 mg
intravenously every 6 months. There were no conﬁrmed cases of
ONJ during a follow up of 84 months [9]. All these studies are
summarized in the Table 1.
Keeping in mind the limitation of these studies by the absence
of long-term follow-up, the mean risk of developing ONJ variesTable 1
The number and percentage of ONJ described in Z-FAST, ZO-FAST and E-ZO-FAST trials.
Patients included in
the study/follow-up
duration
Patients receiving up-
front Zoledronic acid
Number of ONJ Pe
all
Z-FAST 602/60 months 301 0 ONJ conﬁrmed,
2 ONJ possible
0–
ZO-FAST 1065/60 months 532 3 ONJ conﬁrmed,
2 ONJ possible
0.2
E-ZO-FAST 527/12 months 263 2 ONJ conﬁrmed 0.3
ABCSG-12 1803/84 months – 0 ONJ conﬁrmed 0%between 0.23–0.41% in patients receiving immediate or late zole-
dronic acid. This risk increases up to 0.7% in patients receiving
immediate zoledronic acid.4. Discussion
Zoledronic acid has been approved for prevention and treat-
ment of osteoporosis and glucocorticoids-induced osteoporosis,
treatment of Paget's disease, hypercalcemia, multiple myeloma
and bone metastasis. In the particular case of breast cancer, it is
recommended as a monthly administration in breast cancer pa-
tients with bone metastasis and as a biyearly administration in
early breast cancer patients receiving adjuvant aromatase in-
hibitors for AIBL prevention [10].
Zoledronic acid is a high potency aminobiphosphonate with an
osteoclastic inhibiting activity. It is incorporated into the skeleton
without being degraded and consequently decreases bone turn-
over and inhibits of the bone's reparative ability [11,12]. Prolonged
use of zoledronic acid suppresses bone turnover disabling repair of
microdamage [13].
Reports of the side effects of zoledronic acid most commonly
describe bone pain, nausea, fever, fatigue and constipation. ONJ is
an uncommon, but severe, adverse event that has been reported
with prolonged zoledronic acid therapy.
In women with advanced breast cancer and bone metastases,
the use of bisphosphonates in adjunction to hormone therapy or
chemotherapy reduces the SRE occurrence and the SRE rate, as
well as increases the time to skeletal event occurrence [2]. Their
major adverse event remains the ONJ. Effectively, breast cancer
patients receiving bisphophonates represent more than 20% of
patients developing ONJ [14].
Metastatic breast cancer patients treated by zoledronic acid
monthly develop ONJ in 1.2–3.8% with the long-term treatment
[3,4]. On the other hand, biyearly zoledronic acid for AIBL pre-
vention in early breast cancer is complicated with ONJ in less than
0.7% according to our literature review. Unfortunately, these trials
did not report the time of occurrence of the ONJ [6–8]. However,
the AZURE trial used a regimen that consisted of monthly zole-
dronic acid for six doses then every three to six months to com-
pete the 5 years treatment and reported a comparable prevalence
of ONJ [15]. This comparison allows a safe administration of the
“loading dose” of zoledronic acid. Effectively, the pharmacology of
the zoledronic acid characterized by a long half-life correlates well
with this ﬁnding. A recently published abstract, SWOG 0307
compared three different bisphosphonates clodronate, iban-
dronate and zoledronic acid administred in a speciﬁc schedules in
the adjuvant setting of early breast cancer. No evidence of differ-
ences in efﬁcacy by type of bisphosphonate either in the intent to
treat analysis or based on age and menopausal status was detected
between the three arms. At 5 years follow-up, the rate of ONJ was
1.2% in zoledronic acid arm administered monthly for six months
then every 3 months for 2.5 years [16].rcentage of ONJ in
included patients
Percentage of ONJ in pa-
tients receiving upfront Zo-
ledronic acid
Annual risk of ONJ in pa-
tients receiving up front zo-
ledronic acid
0.33% 0–0.66% 0–0.13%
8–0.48% N/A N/A
8% 0.76% 0.76%
– N/A
H.R. Kourie et al. / Journal of Bone Oncology 4 (2015) 77–79 79Denosumab, a fully monoclonal antibody RANKL inhibitor, was
also evaluated at 60 mg every six months instead of zoledronic
acid in patients presenting aromatase inhibitor associated bone
loss in early breast cancer. In ABCSG 18 trial comparing denosu-
mab 60 mg every six months to placebo, 3425 patients were in-
cluded; overall lower number of fractures was demonstrated in
the denosumab arm versus the placebo arm. 35 dental problems
were identiﬁed by proactive monitoring of ONJ during the trial, 31
suspected cases of ONJ were detected but no case was eventually
judged to meet the diagnosis criteria of ONJ [17]. Denosumab
seems to be safer concerning ONJ in the indication compared to
zoledronic acid; a randomized trial comparing these two agents
can only conﬁrm this hypothesis.5. Conclusions
Osteonecrosis of the jaw is a major complication of monthly
biphosphonate regiments that seems to be encountered also in
biyearly administration. But its occurrence remains lower in the
later setting. The literature review on zoledronic acid given every
six months to prevent AIBL, showed a relatively low risk for ONJ
not exceeding 0.7%. Despite this low prevalence, avoidance of
dental manipulation and recommendations of oral hygiene must
be universally respected, regardless of zoledronic acid schedule of
administration.References
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